Antiphospholipid antibodies in patients with inflammatory bowel disease

D. Caccavo, B. Greco, L. Caradonna, G. Leandro, L. Bonomo, E. Jirillo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Antiphospholipid antibodies (e.g. anticardiolipin antibodies; aCL) are frequently associated with thrombotic events. In view of the evidence that thrombotic phenomena may complicate inflammatory bowel disease (IBD), we have measured aCL in patients affected by ulcerative colitis (UC) (n = 30) and Crohn's disease (CD) (n = 22). We demonstrated that 6/30 (20%) of UC and 8/22 (36%) of CD patients showed increased levels of aCL (p <0.004 and p <0.0001, respectively, compared with healthy controls). aCL from IBD patients bound the corresponding antigen more efficiently in the presence of bovine serum which contained β2-glycoprotein I, a lipid-binding inhibitor of coagulation. aCL did not correlate either with disease activity or extent. No patient had clinical manifestations and/or a history of thromboembolism, which can perhaps occur without overt clinical signs. aCL could be a risk factor for intestinal thrombotic phenomena.

Original languageEnglish
Pages (from-to)711-713
Number of pages3
JournalMedical Science Research
Volume24
Issue number10
Publication statusPublished - 1996

Fingerprint

Antiphospholipid Antibodies
Inflammatory Bowel Diseases
Ulcerative Colitis
Crohn Disease
Anticardiolipin Antibodies
Thromboembolism
Glycoproteins
Coagulation
Antigens
Lipids
Serum

Keywords

  • Anti-phospholipid antibodies
  • Crohn's disease
  • Thrombosis
  • Ulcerative colitis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Caccavo, D., Greco, B., Caradonna, L., Leandro, G., Bonomo, L., & Jirillo, E. (1996). Antiphospholipid antibodies in patients with inflammatory bowel disease. Medical Science Research, 24(10), 711-713.

Antiphospholipid antibodies in patients with inflammatory bowel disease. / Caccavo, D.; Greco, B.; Caradonna, L.; Leandro, G.; Bonomo, L.; Jirillo, E.

In: Medical Science Research, Vol. 24, No. 10, 1996, p. 711-713.

Research output: Contribution to journalArticle

Caccavo, D, Greco, B, Caradonna, L, Leandro, G, Bonomo, L & Jirillo, E 1996, 'Antiphospholipid antibodies in patients with inflammatory bowel disease', Medical Science Research, vol. 24, no. 10, pp. 711-713.
Caccavo D, Greco B, Caradonna L, Leandro G, Bonomo L, Jirillo E. Antiphospholipid antibodies in patients with inflammatory bowel disease. Medical Science Research. 1996;24(10):711-713.
Caccavo, D. ; Greco, B. ; Caradonna, L. ; Leandro, G. ; Bonomo, L. ; Jirillo, E. / Antiphospholipid antibodies in patients with inflammatory bowel disease. In: Medical Science Research. 1996 ; Vol. 24, No. 10. pp. 711-713.
@article{e0b067d7bfaa408fb0ec12677cc35838,
title = "Antiphospholipid antibodies in patients with inflammatory bowel disease",
abstract = "Antiphospholipid antibodies (e.g. anticardiolipin antibodies; aCL) are frequently associated with thrombotic events. In view of the evidence that thrombotic phenomena may complicate inflammatory bowel disease (IBD), we have measured aCL in patients affected by ulcerative colitis (UC) (n = 30) and Crohn's disease (CD) (n = 22). We demonstrated that 6/30 (20{\%}) of UC and 8/22 (36{\%}) of CD patients showed increased levels of aCL (p <0.004 and p <0.0001, respectively, compared with healthy controls). aCL from IBD patients bound the corresponding antigen more efficiently in the presence of bovine serum which contained β2-glycoprotein I, a lipid-binding inhibitor of coagulation. aCL did not correlate either with disease activity or extent. No patient had clinical manifestations and/or a history of thromboembolism, which can perhaps occur without overt clinical signs. aCL could be a risk factor for intestinal thrombotic phenomena.",
keywords = "Anti-phospholipid antibodies, Crohn's disease, Thrombosis, Ulcerative colitis",
author = "D. Caccavo and B. Greco and L. Caradonna and G. Leandro and L. Bonomo and E. Jirillo",
year = "1996",
language = "English",
volume = "24",
pages = "711--713",
journal = "Medical Science Research",
issn = "0269-8951",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Antiphospholipid antibodies in patients with inflammatory bowel disease

AU - Caccavo, D.

AU - Greco, B.

AU - Caradonna, L.

AU - Leandro, G.

AU - Bonomo, L.

AU - Jirillo, E.

PY - 1996

Y1 - 1996

N2 - Antiphospholipid antibodies (e.g. anticardiolipin antibodies; aCL) are frequently associated with thrombotic events. In view of the evidence that thrombotic phenomena may complicate inflammatory bowel disease (IBD), we have measured aCL in patients affected by ulcerative colitis (UC) (n = 30) and Crohn's disease (CD) (n = 22). We demonstrated that 6/30 (20%) of UC and 8/22 (36%) of CD patients showed increased levels of aCL (p <0.004 and p <0.0001, respectively, compared with healthy controls). aCL from IBD patients bound the corresponding antigen more efficiently in the presence of bovine serum which contained β2-glycoprotein I, a lipid-binding inhibitor of coagulation. aCL did not correlate either with disease activity or extent. No patient had clinical manifestations and/or a history of thromboembolism, which can perhaps occur without overt clinical signs. aCL could be a risk factor for intestinal thrombotic phenomena.

AB - Antiphospholipid antibodies (e.g. anticardiolipin antibodies; aCL) are frequently associated with thrombotic events. In view of the evidence that thrombotic phenomena may complicate inflammatory bowel disease (IBD), we have measured aCL in patients affected by ulcerative colitis (UC) (n = 30) and Crohn's disease (CD) (n = 22). We demonstrated that 6/30 (20%) of UC and 8/22 (36%) of CD patients showed increased levels of aCL (p <0.004 and p <0.0001, respectively, compared with healthy controls). aCL from IBD patients bound the corresponding antigen more efficiently in the presence of bovine serum which contained β2-glycoprotein I, a lipid-binding inhibitor of coagulation. aCL did not correlate either with disease activity or extent. No patient had clinical manifestations and/or a history of thromboembolism, which can perhaps occur without overt clinical signs. aCL could be a risk factor for intestinal thrombotic phenomena.

KW - Anti-phospholipid antibodies

KW - Crohn's disease

KW - Thrombosis

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=0029950333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029950333&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029950333

VL - 24

SP - 711

EP - 713

JO - Medical Science Research

JF - Medical Science Research

SN - 0269-8951

IS - 10

ER -